n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
4 Stocks Under $10 Moving Higher

4 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM

Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM

Novartis' ceritinib is a next-generation ALK inhibitor already under FDA review as a new treatment for lung cancer.

ARIAD Announces Initiation Of Pivotal Phase 2 ALTA Trial Of AP26113 In Patients With Non-Small Cell Lung Cancer

ARIAD Announces Initiation Of Pivotal Phase 2 ALTA Trial Of AP26113 In Patients With Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who...

The Next Big Biotech Mover: Ariad Pharma

The Next Big Biotech Mover: Ariad Pharma

Ariad Pharmaceuticals could be the next biotech stock setting up for a monster move higher, according to Roberto Pedone.

Perilous Reversal Watch: Ariad Pharmaceuticals (ARIA)

Perilous Reversal Watch: Ariad Pharmaceuticals (ARIA)

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

Ariad Pharmaceuticals (ARIA): Today's Pre-Market Leader Stock

Ariad Pharmaceuticals (ARIA): Today's Pre-Market Leader Stock

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a pre-market leader candidate

ARIAD Reports 2013 Financial Results And Outlines Key Objectives For 2014

ARIAD Reports 2013 Financial Results And Outlines Key Objectives For 2014

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments.

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Ariad Pharmaceuticals was a leading decliner within the drugs industry, falling $0.24 (-2.7%) to $8.63 on light volume

ARIAD To Present At The Cowen And Company 34th Annual Health Care Conference

ARIAD To Present At The Cowen And Company 34th Annual Health Care Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 34 th Annual Health Care Conference being held in Boston.

Ariad Pharmaceuticals (ARIA) Strong In Pre-Market Trading

Ariad Pharmaceuticals (ARIA) Strong In Pre-Market Trading

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a pre-market leader candidate

ARIAD Expands Its Board Of Directors With Appointment Of Alexander J. Denner, Ph.D. Of Sarissa Capital Management

ARIAD Expands Its Board Of Directors With Appointment Of Alexander J. Denner, Ph.D. Of Sarissa Capital Management

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the appointment of Alexander J.

ARIAD To Present At The RBC Capital Markets Healthcare Conference

ARIAD To Present At The RBC Capital Markets Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City.

Ariad Pharmaceuticals (ARIA): Today's Pre-Market Leader Stock

Ariad Pharmaceuticals (ARIA): Today's Pre-Market Leader Stock

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a pre-market leader candidate

5 Stocks Ready to Explode Higher

5 Stocks Ready to Explode Higher

These stocks could be sett9ing up for explosive moves higher soon.

Stock To Watch: Ariad Pharmaceuticals (ARIA) In Perilous Reversal

Stock To Watch: Ariad Pharmaceuticals (ARIA) In Perilous Reversal

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

ARIAD To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year-End 2013 Financial Results On February 25, 2014

ARIAD To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year-End 2013 Financial Results On February 25, 2014

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2013 financial results on Tuesday, February 25, 2014, before the market opens.

'Mad Money' Lightning Round: We Don't Want Molycorp

'Mad Money' Lightning Round: We Don't Want Molycorp

Cramer likes Palo Alto Networks over FireEye and Linn Energy over Breitburn Energy Partners.

Jim Cramer's 'Mad Money' Recap: A Matter of Distrust

Jim Cramer's 'Mad Money' Recap: A Matter of Distrust

Cramer says there are two sides to every earnings report, and the ugly side is where investors are focusing.

Ariad Pharma's Executive Stock Giveaway Kills Takeover Hopes

Ariad Pharma's Executive Stock Giveaway Kills Takeover Hopes

CEO Harvey Berger was just given a truckload of free Ariad shares, which means he's not negotiating himself out of a job at the moment.

ARIAD To Present At The Leerink Swann Global Healthcare Conference

ARIAD To Present At The Leerink Swann Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Global Healthcare Conference being held in New York City.

3 Huge Stocks to Trade (or Not)

3 Huge Stocks to Trade (or Not)

Here's a look at how to trade some of the most active stocks on the market today.

Pre-Market Laggard: Ariad Pharmaceuticals (ARIA)

Pre-Market Laggard: Ariad Pharmaceuticals (ARIA)

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a pre-market laggard candidate

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Ariad Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today

Ariad Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

ARIAD Announces Commercial Agreement For Iclusig (Ponatinib) In Australia

ARIAD Announces Commercial Agreement For Iclusig (Ponatinib) In Australia

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize ...

Ariad Pharma Short Seller Explains Why Takeover Rumor Is Bunk

Ariad Pharma Short Seller Explains Why Takeover Rumor Is Bunk

Both of Ariad's most important drugs -- Iclusig and AP26113 -- will be obsolete in coming years, making an expensive takeover a fool's errand.

Ariad Pharmaceuticals (ARIA) Highlighted As Today's Perilous Reversal Stock

Ariad Pharmaceuticals (ARIA) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

Analyst Reason No. 345 to Upgrade Biotech Stocks: Takeover Rumors in the Foreign Press!

Analyst Reason No. 345 to Upgrade Biotech Stocks: Takeover Rumors in the Foreign Press!

In the past two months, BMO Capital Markets biotech analyst Jim Birchenough has upgrade stocks based on takeover rumors published in overseas newspapers.

Why Ariad Pharmaceuticals (ARIA) Hit a Three-Month High Today

Why Ariad Pharmaceuticals (ARIA) Hit a Three-Month High Today

Ariad Pharmaceuticals hit a three-month high of $9.83 on Friday. By mid-afternoon, volume already had surpassed 80 million shares compared with average daily volume of 26.02 million shares. The stock opened at $7.37, hit a low of $7.35 and then soared to a high by midday of $9.83, its highest total in more than three months.

3 Huge Stocks to Trade (or Not)

3 Huge Stocks to Trade (or Not)

Here's how to trade some of the most active stocks on the market today.